IgAN Clinical Trials

4 recruiting

IgAN Trials at a Glance

29 actively recruiting trials for igan are listed on ClinicalTrialsFinder across 6 cities in 39 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Shanghai, Beijing, and Hangzhou. Lead sponsors running igan studies include The Children's Hospital of Zhejiang University School of Medicine, ADARx Pharmaceuticals, Inc., and Alexion Pharmaceuticals, Inc..

Browse igan trials by phase

Treatments under study

About IgAN Clinical Trials

Looking for clinical trials for IgAN? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new IgAN trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about IgAN clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 29 trials

Recruiting

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

ProlactinomaCushing DiseasePanhypopituitarism+1 more
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)2,000 enrolled1 locationNCT00001595
Recruiting
Phase 2

Chinese Adults With Kidney Disease

Immunoglobulin A Nephropathy (IgAN)IC-MPGNComplement 3 Glomerulopathy (C3G)
ADARx Pharmaceuticals, Inc.30 enrolled10 locationsNCT07522099
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled228 locationsNCT06935357
Recruiting
Phase 2

Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

IgA Nephropathy (IgAN)IgANC3G+2 more
ADARx Pharmaceuticals, Inc.45 enrolled25 locationsNCT06989359
Recruiting
Not Applicable

Clinical Relevance of Modifying RANKL Signaling During Folliculogenesis

OsteoporosisFemale InfertilityNF-κB Ligand+2 more
Peter Humaidan100 enrolled1 locationNCT07546552
Recruiting
Phase 3

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A NephropathyIgAN
Alexion Pharmaceuticals, Inc.510 enrolled267 locationsNCT06291376
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Phase 2

A Study to Assess the Effects of Zigakibart on IgA Nephropathy.

Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals32 enrolled8 locationsNCT07146906
Recruiting
Phase 3

Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

Primary Immunoglobulin A Nephropathy (IgAN)
Novartis Pharmaceuticals31 enrolled15 locationsNCT06994845
Recruiting
Phase 3

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Early Phase 1

iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009

Huntington DiseasePositron Emission TomographyImaging+5 more
CHDI Foundation, Inc.27 enrolled1 locationNCT06634628
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Phase 3

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

IgA Nephropathy (IgAN)
Haisco Pharmaceutical Group Co., Ltd.370 enrolled1 locationNCT07390123
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases

IgA Nephropathy (IgAN)Membranous NephropathyANCA-associated Vasculitis (AAV)/ANCA-associated Glomerulonephritis (AAGN)+2 more
Grit Biotechnology30 enrolled1 locationNCT07389499
Recruiting
Phase 2

Atacicept in Multiple Glomerular Diseases

IgANNephrotic SyndromeFSGS+2 more
Vera Therapeutics, Inc.200 enrolled1 locationNCT06983028
Recruiting

A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

IgA Nephropathy (IgAN)Early Initial Therapy
Sichuan Provincial People's Hospital200 enrolled1 locationNCT06676007
Recruiting
Phase 2

A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA Nephropathy

IgA Nephropathy (IgAN)
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.30 enrolled1 locationNCT07305974
Recruiting
Early Phase 1

Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease

Autoimmune DiseasesSystemic Lupus ErthematosusMulti-Drug Resistant Nephrotic Syndrome+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT06792799
Recruiting
Phase 2

Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)

IgA Nephropathy (IgAN)
Mayo Clinic16 enrolled2 locationsNCT06676579
Recruiting

RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN)

IgA Nephropathy (IgAN)
Assistance Publique - Hôpitaux de Paris800 enrolled1 locationNCT06926244